CDT Stock Risk & Deep Value Analysis
CDT Equity Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CDT Stock
We analyzed CDT Equity Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CDT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CDT Risk Analysis & Red Flags
What Could Go Wrong
CDT is currently burning cash with no clear path to profitability. Continued operational losses will necessitate further highly dilutive capital raises (like the existing $76.1M ATM capacity), which could severely depress the share price and potentially lead to delisting if the market cap or price falls below exchange minimums, ultimately wiping out shareholder value.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Persistent unprofitability (anticipated $39.1M net loss) and negative TTM net income.
- ⚠
Heavy reliance on dilutive equity financing (Form S-3 for 22M+ shares resale, equity lines).
- ⚠
Lack of transparency and detailed financial reporting in public search results.
- ⚠
History of multiple reverse stock splits.
- ⚠
Market cap ($25.26M, previously $0.01B reported in prompt) is extremely small and highly susceptible to volatility and delisting risk.
Upcoming Risk Events
- 📅
Continued reliance on highly dilutive equity raises
- 📅
Failure of Sarborg AI initiatives to progress or secure partnerships
- 📅
Adverse outcomes or lack of progress with Tapinarof IP monetization
When to Reconsider
- 🚪
Announcement of substantial new dilutive capital raises that significantly increase shares outstanding (e.g., >20% dilution).
- 🚪
Failure to announce any meaningful progress on Sarborg AI or Tapinarof IP within the next 6-9 months.
- 🚪
Share price consistently trades below $1.00 for an extended period, signaling potential delisting from Nasdaq.
Unlock CDT Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does CDT Equity Inc (CDT) Do?
Market Cap
$10.93M
Sector
Healthcare
Industry
Biotechnology
Employees
6
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Visit CDT Equity Inc WebsiteInvestment Thesis
CDT Equity Inc. is a highly speculative investment representing a bet on the long-shot potential of its 20% equity stake in Sarborg AI, which is developing AI-driven solutions for rare diseases and plant biology, alongside potential value from its Tapinarof IP. A successful breakthrough or significant partnership in either area, despite the company's severe financial challenges and dilution, could lead to outsized returns from its current micro-cap valuation. This is a pure venture-stage play for capital that can withstand total loss.
Is CDT Stock Undervalued?
Unlock the full AI analysis for CDT
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CDT Price Targets & Strategy
12-Month Target
$4.50
Bull Case
$8.00
Bear Case
$0.50
Valuation Basis
Highly speculative; based on the successful execution of early strategic initiatives (e.g., Sarborg AI milestones, Tapinarof IP licensing) leading to a modest re-rating to 2x-3x current price, reflecting a market cap around $50M-$75M if it can attract further institutional interest on strategic progress.
Entry Strategy
Due to extreme volatility and limited information, a highly speculative entry at current levels ($2.00-$2.50) is only for investors with high risk tolerance. Consider dollar-cost averaging if significant positive catalysts emerge.
Exit Strategy
Take profit on any significant rallies (e.g., 50-100%+ gains) driven by news flow. Implement a tight stop-loss below key psychological support levels, such as $1.50 or $1.00, to limit capital at risk.
Portfolio Allocation
0.1% for aggressive risk tolerance; considered 'speculative capital' only.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does CDT Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Nascent/Undefined
Moat Sources
1 Identified
Extremely low durability; the potential moat relies entirely on Sarborg AI's future scientific breakthroughs and commercial success, and the successful monetization and defense of Tapinarof IP. Both are highly uncertain and subject to intense competition and capital requirements.
Moat Erosion Risks
- •Significant competition from well-funded biotech and AI companies.
- •Challenges in protecting and commercializing intellectual property.
- •Dependence on Sarborg AI's independent progress and funding.
CDT Competitive Moat Analysis
Sign up to see competitive advantages
CDT Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral; likely a niche following of highly speculative investors, with significant skepticism due to past performance.
Institutional Sentiment
Negative; previous analyst 'Sell' rating, no identified institutional buying or positive upgrades.
Insider Activity (Form 4)
No specific Form 4 filings identified for management. However, a Form S-3 filed January 29, 2026, registers 22,846,452 shares for resale tied to consulting fees, an equity line, and settlements, indicating potential selling pressure from affiliates/early investors, not necessarily management directly.
Options Flow
Normal options activity; unlikely to have significant or unusual institutional options activity given its market capitalization and liquidity profile.
Earnings Intelligence
Next Earnings
Unavailable; historically, US public companies report Q1 earnings within 45 days of quarter end (mid-May for Q1 2026).
Surprise Probability
Low; high uncertainty and absence of consensus estimates make surprises unpredictable, but likely negative given historical unprofitability.
Historical Earnings Pattern
Undetermined due to lack of specific historical earnings reaction data in research; however, deeply unprofitable companies tend to be highly volatile around earnings, often selling off on continued losses or guidance.
Key Metrics to Watch
Competitive Position
Top Competitor
Recursion Pharmaceuticals (RXRX)
Market Share Trend
N/A; too early stage to have measurable market share in any defined segment.
Valuation vs Peers
Undetermined due to lack of financial metrics; however, given its early stage and unprofitability, it likely trades on a speculative 'hope' valuation rather than traditional metrics, making direct peer comparison difficult.
Competitive Advantages
- •20% equity stake in Sarborg AI, with its PRISM framework for cross-species AI connectivity
- •Potential intellectual property portfolio related to Tapinarof
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CDT Stock Higher?
Near-Term (0-6 months)
- •Further updates or partnerships related to Sarborg AI's PRISM framework (0-6 months)
- •Any concrete licensing or development agreements for Tapinarof IP (0-6 months)
Medium-Term (6-18 months)
- •Successful (non-dilutive) funding for pipeline development (6-18 months)
- •Proof-of-concept or early-stage trial results for Sarborg AI-derived assets (6-18 months)
Long-Term (18+ months)
- •Significant commercialization event or acquisition of Sarborg AI (18+ months)
- •Establishment of a recurring revenue stream from IP licensing or drug development (18+ months)
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CDT?
- ✓
Announcement of significant partnerships or funding for Sarborg AI that validates its technology.
- ✓
Any clear pathway to profitability or self-sustaining operations, reducing reliance on dilutive financing.
- ✓
Positive clinical development milestones or licensing deals for Tapinarof IP.
Bull Case Analysis
See what could go right with Premium
Competing with CDT
See how CDT Equity Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
CDT Equity Inc CDT | $10.9M | 1.2 | — | — | — | — | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How CDT Equity Inc Makes Money
CDT Equity Inc. operates as a holding company with speculative investments primarily in the biotechnology and artificial intelligence sectors. Its core strategy revolves around a 20% equity stake in Sarborg AI, which focuses on developing AI solutions for rare diseases and plant biology, and leveraging its intellectual property portfolio related to Tapinarof, a dermatology drug. The company's business model currently involves minimal to no operational revenue, with its existence largely dependent on raising capital through equity financing to fund its limited operations, strategic investments, and settle past liabilities. Future revenue, if any, is anticipated from licensing agreements, royalties, or the eventual monetization of its equity stake in Sarborg AI, rather than direct product sales.
Read Full Business Model BreakdownFAQ
What is the DVR Score for CDT Equity Inc (CDT)?
As of April 30, 2026, CDT Equity Inc has a DVR Score of 1.2 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of CDT Equity Inc?
CDT Equity Inc's market capitalization is approximately $10.9M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does CDT Equity Inc use?
CDT is the ticker symbol for CDT Equity Inc. The company trades on the NCM.
What is the risk level for CDT stock?
Our analysis rates CDT Equity Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the CDT DVR analysis updated?
Our AI-powered analysis of CDT Equity Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CDT (CDT Equity Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.